Evidence map›Paper›PMID 39980281›Full record

ReviewCurrent pharmaceutical design2025

A Review of Anticancer Activity of

Reza Zare-Bidoki, Ali Afrasiabi, Fatemeh Zahra Hajatmand-Targhi, Hossein Rahimi, Seyyed Majid Bagheri

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Reza Zare-BidokiFaculty of Medicine, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Ali AfrasiabiFaculty of Medicine, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Fatemeh Zahra Hajatmand-TarghiFaculty of Medicine, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Hossein RahimiDepartment of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyyed Majid BagheriDepartment of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is a challenging and lethal illness, with the number of individuals affected on the rise, particularly in developing nations. This disease incurs significant expenses for both patients and governments annually. Conversely, even with various methods and treatments in use, the mortality rate remains elevated. Additionally, traditional therapies come with numerous side effects, and drug resistance presents another obstacle for physicians. Consequently, discovering new drugs derived from natural sources may be a method to combat cancer. Ferula plants contain different metabolites, including monoterpenes, sulfide compounds, and polyphenols that are beneficial in cancer therapy.

objectiveThis article was assembled to gather evidence and literature concerning the anticancer properties of compounds derived from these plants. METHODOLOGY: This review article was created by exploring the term

resultsResults revealed that quite extensive research has been done in this area, indicating that the compounds may serve as novel medications for cancer therapy.

conclusionSubsequent research should encompass animal studies or clinical trials, focusing on assessing toxicity and identifying effective doses against cancer to facilitate the application of these natural derivatives in cancer treatment.

Indexed as

Antineoplastic Agents, PhytogenicFerulaNeoplasmsPlant ExtractsAnimalsHumansAntineoplastic Agents, PhytogenicPlant Extractsaction mechanismanticanceressential oilFerula constituentsisolated componentsmonoterpene.

Identifiers

PMID39980281

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.